CM24 is a first-in-class, clinical-stage immune checkpoint inhibitor mAb targeting CEACAM1, with significant potential to treat multiple cancers.
NT219 is a first-in-class, novel small molecule targeting both IRS1/2 and STAT3, important oncogenic drivers and major drug resistance pathways in many hard-to-treat cancers.
IM1240 is a conditionally-activated tri-specific antibody that engages both T cells and NK cells and 5T4 antigen (5T4xCD3xNKG2A)
Presented at the ASCO annual meeting 2022
Published in Nature Cancer, October 2021
Presented at ASCO annual meeting 2021
Presented at the AACR annual meeting 2021
Presented at the AACR annual meeting 2020
Presented at the 2020 multidisciplinary Head and Neck Cancers Symposium
Presented at the 2019 AACR Special Conference Pancreatic Cancer
Presented at the Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy
Presented at the AACR annual meeting 2017
Presented at the AACR special conference: Cancer Metastasis, November, 2022
Presented at the AACR annual meeting April, 2022
Presented at the ESMO annual meeting 2021
Presented at the ASCO annual meeting 2020